Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Disease In Women

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    488 result(s) found for: Cardiovascular Disease In Women. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005532-32 Sponsor Protocol Number: KWI-NIC-02 Start Date*: 2009-03-13
    Sponsor Name:Kwizda Pharma
    Full Title: The bioavailability of nicorandil in humans: A pilot study to investigate the variability of its pharmacokinetic parameters in healthy volunteers.
    Medical condition: The bioavailability of Nicorandil in humans: A pilot study to investigate the variability of the pharmacokinetic parameters in healthy volunteers. The IMP Nicorandil (2-(pyridine-3-carbonylamino)et...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007649 Cardiovascular disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003946-34 Sponsor Protocol Number: OB-401 Start Date*: 2013-10-30
    Sponsor Name:VIVUS, Inc.
    Full Title: A Qsymia™ CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease
    Medical condition: Cardiovascular Disease in overweight and obese subjects
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000215-89 Sponsor Protocol Number: CL2-16257-099 Start Date*: 2013-06-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, d...
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005288-33 Sponsor Protocol Number: EMI111784 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Research & Development, LtdD
    Full Title: Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound
    Medical condition: Atherosclerotic plaque within the carotid artery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002466-35 Sponsor Protocol Number: ACTRN012607000099426 Start Date*: 2008-03-11
    Sponsor Name:Imperial Ciollege [...]
    1. Imperial Ciollege
    2. St Mary's NHS Trust
    3. University Medical Center Utrecht
    Full Title: A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002856-18 Sponsor Protocol Number: RB12.079 Start Date*: 2013-03-22
    Sponsor Name:CHRU de Brest
    Full Title: ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10050441 Chronic renal insufficiency LLT
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003486-26 Sponsor Protocol Number: 1002-047 Start Date*: 2017-05-24
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Ad...
    Medical condition: Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004084-39 Sponsor Protocol Number: 1002-048 Start Date*: 2017-04-19
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patie...
    Medical condition: This study is to assess the efficacy of bempedoic acid 180 mg/day versus placebo in decreasing low-density lipoprotein cholesterol (LDL-C) when added to ezetimibe therapy in patients with high LDL-...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    19.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-004026-30 Sponsor Protocol Number: CUSA-081-HEM-02 Start Date*: 2022-02-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: READY 2: A PHASE 3, OPEN LABEL, SINGLE ARM STUDY ON THE USE OF CUSA-081 FOR DYSFUNCTIONAL CENTRAL VENOUS ACCESS DEVICES (CVADs)
    Medical condition: Catheter Occlusion Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017242-30 Sponsor Protocol Number: D5132C00001 Start Date*: 2010-12-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Sali...
    Medical condition: Myocardial Infarction, Cardiovascular Death, Atherothombosis, Stroke
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) RO (Completed) CZ (Completed) SK (Completed) PL (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) NO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004394-49 Sponsor Protocol Number: LIB003-007 Start Date*: 2021-08-12
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at ...
    Medical condition: Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002169-30 Sponsor Protocol Number: GlaMet1 Start Date*: 2008-09-19
    Sponsor Name:Greater Glasgow Health Board, Research and Development Department [...]
    1. Greater Glasgow Health Board, Research and Development Department
    2. Senior Contracts Manager,Research and Enterprise,University of Glasgow
    Full Title: A randomised placebo-controlled trial of metformin on progression of carotid atherosclerosis in non-diabetic patients with cardiovascular disease treated with conventional risk reducing agents
    Medical condition: Participants must have definite coronary heart disease: either a previous myocardial infarction or positive findings on coronary angiogram. They can have normal glucose tolerance, impaired fasting ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006527-30 Sponsor Protocol Number: 2008-006527-30 Start Date*: 2008-12-17
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Preventing Breast cancer through Assumption of Metformin, Diet and Physical Activity
    Medical condition: women affected by metabolic syndrome defined by at least three out of five metabolic factors: 1-glucose >110 mg/100 mL 2-triglycerides >150mg/100mL 3-HDL cholesterol <50 mg/100mL 4-waist circum...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038604 SOC
    9.1 10029104 SOC
    9.1 10007649 PT
    9.1 10022891 SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001398-97 Sponsor Protocol Number: 20110118 Start Date*: 2012-10-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Co...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020604 Hypercholesterolemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed) GR (Completed) LT (Completed) BE (Completed) IT (Completed) NL (Completed) DK (Completed) AT (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) EE (Completed) IS (Completed) GB (Completed) DE (Completed) BG (Completed) SE (Completed) LV (Completed) IE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000860-25 Sponsor Protocol Number: CSPP100E2337 Start Date*: 2007-07-27
    Sponsor Name:Novartis Farmacéutica, SA
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg...
    Medical condition: Diabetes tipo 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004376-11 Sponsor Protocol Number: AZM-MD-302 Start Date*: 2012-05-15
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizat...
    Medical condition: Ventricular arrhythmia in patients with implantable cardioverter-defibrillator (ICD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10047281 Ventricular arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Ongoing) SK (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) BG (Ongoing) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003387-18 Sponsor Protocol Number: 2007CV23 Start Date*: 2008-12-08
    Sponsor Name:University of Dundee
    Full Title: The Effects of Oral Vitamin D Supplementation on Cardiovascular Disease Risk in UK South Asian Women
    Medical condition: Randomised, placebo controlled, parallel group, double blinded study to investigate if oral supplementation of vitamin D will improve cardiovascular function and metabolic and inflammatory paramete...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047066 Vascular disorders NEC HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003189-16 Sponsor Protocol Number: R727-CL-1532 Start Date*: 2016-12-22
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial H...
    Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia with High and Very High Cardiovascular Risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA